Aquilo Capital Management, LLC, 10% Owner at Spero Therapeutics, Inc. (SPRO), bought 125,000 shares at $11.59 ($1.4M) on 2022-01-31, disclosed to the SEC on 2022-02-01.
Open-market purchase of $1.4M SPRO by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| SPRO | BUY | 2022-02-23 | $274K | — | Filing → |
| SPRO | BUY | 2022-01-20 | $1.2M | — | Filing → |
| SPRO | BUY | 2022-01-12 | $229K | — | Filing → |